Forecast

The analysts' average price target is +169,09€ (+60,84%). The median is +167,50€ (+59,33%).

Buy	33
Hold	1
Sell	1

News Go to news feed

Japan grants Insmed approval for lung drug Brensocatib

Japan’s Ministry of Health has approved BRINSUPRI (Brensocatib 25 mg) from Insmed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. The once-daily oral therapy is the first treatment approved in Japan for NCFB and complements existing approvals in the US and Europe. The decision is based on the phase-3 ASPEN study, which showed a reduction in pulmonary exacerbations and positive secondary endpoints over 52 weeks; common adverse events included COVID-19, nasopharyngitis, cough and headache. » More on de.investing.com
Insmed raises annual forecast after strong Brinsupri sales

Insmed reports strong Q2 figures and a jump in sales of its lung drug Brinsupri, whose revenue rose quarter-on-quarter by 48.7% to $309.2 million. In response, management raised the revenue outlook for 2026 to as much as $1.87 billion, thereby beating consensus estimates. The stock reacted with notable price gains and increased trading volume. » More on finanzen.net
Baron Health Care Fund remains bullish on Insmed despite Brinsupri sales miss

In its Q2 2026 investor letter, Baron Health Care Fund said it remains positive on Insmed, viewing its three lead pulmonology assets as able to generate more than $8 billion in peak sales and Brinsupri alone as a $5 billion-plus opportunity. The fund noted shares fell after first-quarter Brinsupri sales missed aggressive expectations and early signs of higher treatment discontinuations, and selling was amplified by Insmed's exit from the Nasdaq-100. Baron highlighted long-term upside from Brinsupri and from TPIP as a once-daily inhaled therapy with potential for better efficacy, and affirmed confidence in the company's fundamentals despite near-term headwinds. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Insmed has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Insmed had revenue of 372.82m€ and net profit of −11.60m€

(EUR)	Jun 2026	YoY
Revenue	+372.82m	309,09%
Gross profit	+313.92m	366,36%
Net profit	−11.60m	95,75%
EBITDA	+12.41m	104,92%

Fundamentals

Metric	Value
Market capitalization	+23.07b€
Number of shares	216.75m
52-week high/low	+182,75€ - +77,64€
Dividends	No
Beta	0,79
P/E ratio	−30,14
PEG ratio	−1,20
P/B ratio	+35,55
P/S ratio	+23,60

Company profile

Insmed Incorporated, ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Therapien für Patienten mit schweren und seltenen Krankheiten. Das Unternehmen bietet ARIKAYCE für die Behandlung von Mycobacterium avium complex-Lungenerkrankungen als Teil einer antibakteriellen Kombinationsbehandlung für erwachsene Patienten an. Außerdem entwickelt es Brensocatib, einen oralen reversiblen Inhibitor der Dipeptidylpeptidase 1 zur Behandlung von Patienten mit Bronchiektasen und anderen neutrophilen Erkrankungen, sowie Treprostinil Palmitil Inhalationspulver, eine inhalative Formulierung des Treprostinil-Prodrugs Treprostinil Palmitil zur Behandlung der pulmonalen arteriellen Hypertonie und anderer seltener Lungenerkrankungen. Insmed Incorporated wurde 1988 gegründet und hat seinen Hauptsitz in Bridgewater, New Jersey.